Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic cytokine that stimulates the differentiation and function of hematopoietic cells. GM-CSF has been implicated in nervous system function. The goal of the present study was to understand the effects of hypoxia-induced GM-CSF on neural stem cells (NSCs) in a model of spinal cord injury (SCI). GM-CSF-overexpressing NSCs were engineered utilizing a hypoxia-inducible gene expression plasmid, including an Epo enhancer ahead of an SV promoter (EpoSV-GM-CSF). Cells were then subjected to hypoxia (pO 2 , 1%) or a hypoxia-mimicking reagent (CoCl 2 ) in vitro. The progression of time of GM-CSF expression was tracked in EpoSV-GM-CSF-transfected NSCs. Overexpression of GM-CSF in undifferentiated and differentiated NSCs created resistance to H 2 O 2 -induced apoptosis in hypoxia. NSCs transfected with EpoSV-GM-CSF or SV-GM-CSF were transplanted into rats after SCI to assess the effect of GM-CSF on NSC survival and restoration of function. Moreover, a significantly higher amount of surviving NSCs and neuronal differentiation was observed in the EpoSV-GM-CSF-treated group. Significant improvement in locomotor function was also found in this group. Thus, GM-CSF overexpression by the Epo enhancer in hypoxia was beneficial to transplanted NSC survival and to behavioral improvement, pointing toward a possible role for GM-CSF in the treatment of SCI.
INTRODUCTION
Neural stem cells (NSCs) have been shown to migrate to, and subsequently differentiate within and near, injury sites in both the brain and spinal cord. 1, 2 As such, NSCs have been investigated increasingly as a potential cell replacement strategy to treat various central nervous system (CNS) disorders, including spinal cord injury (SCI).
Although NSCs show promise as donor cells for cell replacement after neurological damage, the environment surrounding the injured spinal cord is not conducive to the survival of the transplanted cells. The pathological primary and secondary cellular effects triggered by CNS trauma include minimally transient hypoxia, increased extracellular calcium and potassium concentrations, increased glutamate release and overproduction of reactive oxygen species. [3] [4] [5] Although many methods have been developed to allow NSC transplants to overcome environmental challenges after SCI and improve engraftment with host tissue, 6-8 the condition of hypoxia creates an inhospitable environment for NSCs in the injured spinal cord. But, even though hypoxia presents challenges to the proliferation of NSCs after SCI, spinal cord hypoxia could be useful for activating specific gene expression patterns within cell transplants.
Hypoxia has been used successfully to induce gene expression. A plasmid with the erythropoietin enhancer and Simian vacuolating virus 40 (SV40) promoter produces tightly controlled luciferase expression in a model of ischemic injury. 9 Additionally, using a hypoxia-induced expression system, 10 vascular endothelial growth factor (VEGF) gene expression was shown to increase in murine N2a cells after SCI. Gene therapy with hematopoietic growth factors is an interesting strategy for the treatment of CNS traumatic disorders that result in various degrees of hypoxia and ischemic neural tissue damage.
In this study, we used an erythropoietin enhancer as a hypoxiainducible gene expression tool to overcome the potentially inhospitable milieu in the injured spinal cord and to improve the engraftment of NSCs with host neural tissue. Like other hematopoietic growth factors, 11, 12 the granulocyte-macrophage-colony stimulating factor (GM-CSF) has roles in not only hematopoietic cell generation, but also the survival of CNS dopaminergic neurons, 13 inhibition of CNS glial scar formation and neuroprotective treatment after SCI. 14 GM-CSF can enhance the proliferation of neural precursor cells in vitro, and has been suggested to facilitate the recovery of locomotor function after SCI in the adult mouse. 15 Therefore, we hypothesized that hypoxia-specific GM-CSF overexpression would give NSCs a greater window of survival in the inhospitable environment of the injured spinal cord after transplantation. In short, GM-CSF overexpression by NSCs would be activated via the erythropoietin enhancer and SV40 promoter as a result of the hypoxic conditions within the injured spinal cord.
RESULTS

Increased GM-CSF expression by NSCs is activated by in vitro hypoxia
We used double-promoter plasmids to assess the transfection efficacy and expression of GM-CSF. The double promoter plasmids contained an EF1 promoter for the consistent expression of DsRed as a measure of transfection efficiency, and an SV40 promotor for GM-CSF expression (Figure 1a) . To demonstrate the overexpression of genes in hypoxic conditions, the Epo enhancer was placed in front of an SV40 promoter (Figure 1a, right) . This hypoxia-inducible gene expression system displayed efficient delivery and significant transcriptional regulation of luciferase as a reporter gene under hypoxia in vitro. 16 These constructs were confirmed by comparing restriction fragments and by sequencing analysis. To evaluate the protective effects of GM-CSF overexpression in hypoxia, we prepared untransfected NSCs, SV-GM-CSF-transfected NSCs and EpoSV-GM-CSFtransfected NSCs using Lipofectamine 2000. After 4 h of transfection, followed by stabilization for 24 h, more than 80% of NSCs showed red fluorescence (Figure 1b) , indicating successful transfection of the GM-CSF construct. As shown in Figure 1c , the mRNAs of GM-CSF receptor a and b subunits were detected in NSCs by reverse transcription-PCR. To test whether GM-CSF overexpression can be induced by hypoxia, NSCs were first engineered with the plasmid constructs. Then reverse transcription-PCR was performed after cells were placed in a hypoxic chamber (pO 2 , 1%) for 24 h of incubation, or exposed to a hypoxia-mimicking reagent (cobalt chloride, CoCl 2 , 200mM) for 24 h. NSCs transfected with EpoSV-GM-CSF strongly expressed GM-CSF in response to both hypoxia and CoCl 2 treatment, even though GM-CSF expression in SV-GM-CSF-transfected NSCs increased only slightly, compared with expression in untransfected NSCs (Figure 1d) .
To examine the time course of gene expression, NSCs were analyzed at 1, 3, 6, 12 and 24 h after stabilization from transfection. GM-CSF expression in EpoSV-GM-CSF-transfected NSCs showed a gradual increase in response to either hypoxia or CoCl 2 in a time-dependent manner ( Figure 2a ). Even though GM-CSF expression in SV-GM-CSF-transfected NSCs considerably increased in the hypoxic chamber, compared with the expression in untransfected NSCs, the induction in SV-GM-CSF-transfected NSC did not occur again in CoCl 2 treatment. EpoSV-GM-CSF NSCs showed a significantly higher expression of GM-CSF after 6 h in hypoxia. In CoCl 2 treatment, GM-CSF induced significantly in EpoSV-GM-CSF-transfected NSCs after 3 h. Similarly, enzyme-linked immunosorbent assay (ELISA) results showed that Epo-GM-CSF NSCs secreted GM-CSF in a time-dependent manner, producing statistically significant differences in GM-CSF expression at 12 and 24 h when treated with CoCl 2 , compared with the expression in the control group and in the SV-GM-CSF group (Figure 2b) .
Overexpression of GM-CSF by NSCs counteracts apoptosis and promotes cell survival in vitro To examine the potential protective effects of hypoxia-induced GM-CSF on undifferentiated NSCs, the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay for apoptotic cell profiles was performed as previously described. 17 NSCs were treated with 500 mM of hydrogen peroxide (H 2 O 2 , 30%) for 24 h in hypoxia. We counted TUNEL-positive cells in three randomly selected areas for each group of NSCs. There were 22.0±2.7 TUNEL-positive cells in the untransfected NSC group, 17.7 ± 2.5 TUNEL-positive cells in the SV-GM-CSF NSC group and 5.3 ± 1.5 TUNEL-positive cells in the EpoSV-GM-CSF NSC group. The number of TUNEL-positive cells was significantly higher in the control and SV-GM-CSF groups, whereas the EpoSV-GM-CSF group showed the lowest number of TUNEL-positive cells (Figure 3a) . Averages are graphed in Figure 3b .
When apoptosis occurs, phosphatidyl serine is released from the cytoplasmic cell membrane, which is followed by the alteration of the cell membrane phospholipid bilayer. Three undifferentiated groups of NSCs (untransfected NSCs, SV-GM-CSF-transfected NSCs and EpoSV-GM-CSF-transfected NSCs) were treated with 500 mM of H 2 O 2 for 24 h in hypoxia to confirm phosphatidyl serine exposure following apoptosis. After the hypoxia exposure, cells were harvested. Fluorescence-activated cell sorting analysis was performed by annexin-V fluorescein isothiocyanate interaction with phosphatidyl serine. 7 The percentage of annexin-V-positive cells was 30.3±2.1% in untransfected NSCs, 23.7±2.1% in SV-GM-CSF-transfected NSCs and 10.3 ± 0.6% in EpoSV-GM-CSF NSCs. The percentage of annexin-V-positive cells was significantly lower in EpoSV-GM-CSF NSCs, compared with the percentages in other groups. Thus, hypoxiainducible GM-CSF expression prevented cell death after H 2 O 2 treatment (Figure 3c ). Averages are graphed in Figure 3d .
To confirm that differentiation of GM-CSF-engineered NSCs alters the ability of NSCs to survive the apoptotic conditions of H 2 O 2 exposure, we tested the responses of differentiated NSCs to H 2 O 2 injury. To first induce differentiation, NSCs were treated with 1 mM retinoic acid for 7 days. 18 Following the formation of prominent neuronal in vitro networks, NSCs were exposed to hypoxia for 24 h with 500 mM of H 2 O 2 and harvested. Total mRNA was isolated to analyze the expression of the neuronal marker b-III tubulin and the astrocyte marker GFAP (Figure 4a ). b-III tubulin expression in EpoSV-GM-CSF NSCs was found to be twice as strong as the expressions in control NSCs and in SV-GM-CSF NSCs. In contrast, GFAP expression in EpoSV-GM-CSF NSCs was lower than the expressions in SV-GM-CSF NSCs and in untransfected NSCs. A TUNEL assay was then performed (Figure 4b ). We counted three randomly selected areas for each group. The number of TUNELpositive cells was 9.7±0.6 in the untransfected NSC group, 8±1.7 in the SV-GM-CSF NSC group and 2.7 ± 1.5 in the EpoSV-GM-CSF NSC group (Figure 4c ). Hypoxia-induced overexpression of GM-CSF in the EpoSV-GM-CSF group led to a significantly lower amount of TUNEL-positive cells, compared with the amount in the SV-GM-CSF and control groups. This result suggests neuronal protection as a possible role of GM-CSF.
GM-CSF overexpression enhances NSC survival after transplantation into the injured adult rat spinal cord
To demonstrate that GM-CSF decreases apoptosis of the implanted NSCs and enhances NSC survival after transplantation, EpoSV-GM-CSF-and SV-GM-CSF-transfected NSCs were transplanted into adult male Sprague-Dawley rats. Six groups of animals were used for NSCs transplantation. Group 1 received SV-GM-CSF-transfected NSCs without SCI (n¼3, 300 000 cells per 5 ml). Group 2 received EpoSV-GM-CSF-transfected NSCs without SCI (n¼3, 300 000 cells per 5 ml). Groups 3-6 received SCI. SCI was performed by clip compression at the T9 level for 10 min. After compression, NSCs were transplantated into the epicenter of the injury. After SCI, group 3 received only phosphate-buffered saline (PBS; n¼12, 5 ml), whereas group 4 received DsRed-transfected NSC (n¼12, 300 000 cells per 5 ml). Group 5 received SV-GM-CSF-transfected NSCs (n¼12, 300 000 cells per 5 ml), whereas group 6 received EpoSV-GM-CSF-transfected NSCs (n¼12, 300 000 cells per 5 ml).
At 2 weeks after NSC transplantation, grafted NSCs were detected using DsRed fluorescence. NSCs injected into the normal spinal cord of rats were found clustered together (Figure 5a , left). In contrast, NSCs injected into the injured epicenter were found in various locations, with DsRed-positive cells located some distance away from the injury site (Figure 5a , right). Because DsRed fluorescence intensity stained for gene expression as well as for cell survival, optical densities of DsRed fluorescence were measured using MetaMorph software ( Figure 5b ). As shown in Figures 5a and b, NSCs that overexpressed GM-CSF had a significantly greater presence in injured tissue than in SV-GM-CSF normal or injured tissues, or in EpoSV-GM-CSF normal tissues.
To evaluate cell survival resulting from the anti-apoptotic factor, we performed reverse transcription-PCR. The presence of the antiapoptotic genes Bcl-2 and Bcl-xL, as well as the GM-CSF expression, noticeably increased in the EpoSV-GM-CSF-transfected NSCs group compared with all other groups ( Figure 5c ). Next, to confirm cell viability in the rat spinal cord after transplantation, we identified apoptotic cells using a TUNEL assay. We compared the DsRedtransfected NSC group, the SV-GM-CSF-transfected NSC group and the EpoSV-GM-CSF-transfected NSC group. . One day after transfection with lipofectamine, each NSC group was placed in normoxia, hypoxia or normoxia with CoCl 2 (200 mM). Cells and cultured media were harvested for RNA isolation and the measurement of secreted GM-CSF at 0, 3, 6, 12, and 24 h was done. (a) Real time PCR performed by SYBR. GM-CSF gene expression increased significantly in a time-dependent manner after exposure to hypoxia or CoCl 2 , especially in the EpoSV-GM-CSF group after 12 h. (b) ELISA assay performed using harvested media at each time point. A plate coated with an anti-GM-CSF antibody was used to detect secreted GM-CSF. GM-CSF secreted by EpoSV-GM-CSF increased significantly after 12 h in hypoxia and CoCl 2 compared with SV-GM-CSF. *Indicates time at which GM-CSF expression in the EpoSV-GM-CSF group was significantly stronger than the expression of the untransfected NSC group and of the SV-GM-CSF group (Po0.05). # Indicates time at which GM-CSF expression in the SV-GM-CSF group was significantly stronger than that of the untransfected NSC group (Po0.05). Data are shown as mean ± s.d.
compared with the DsRed-transfected NSC group and the SV-GM-CSF-transfected NSC group.
Transplantation of EpoSV-GM-CSF NSCs augment neuronal differentiation in SCI At 6 weeks after transplantation, neuronal differentiation of grafted NSCs was examined. Many surviving NSCs were found in the EpoSV-GM-CSF NSC group. The EpoSV-GM-CSF NSC group expressed significantly more of the neuronal marker b-III tubulin than did the SV-GM-CSF group (Figure 6a ). The quantity of the astrocyte marker GFAP, though, was not statistically different among groups. Most DsRed-fluorescent-surviving EpoSV-GM-CSF NSCs showed co-localized staining with MAP-2, a neuronal marker (Figure 6b ). All animals were observed until they were killed. During these 6 weeks of observation, Basso, Beattie and Bresnahan locomotor assessment was performed by three individuals who were unaware of the conditions for each group. Scores from 4 groups (PBS group, NSCtransplanted group, SV-GM-CSF-transplanted group and EpoSV-GM-CSF-transplanted group) were compared, and although the SV-GM-CSF-transfected NSC group produced better scores than those of the PBS group, this improvement was only demonstrated in the first 3 weeks of the experiment. However, as portrayed in Figure 6c , the EpoSV-GM-CSF-transfected NSC group showed the most significant functional recovery after 2 weeks of transplantation compared with the progress made by the other three groups.
DISCUSSION
After SCI, the environment within and surrounding the injured tissue poses challenges for the survival, proliferation, migration and differentiation of NSC grafts. 2, 19, 20 Many NSC transplantation studies have reported poor survival rates of newly transplanted cells after SCI. 20, 21 However, recent studies have indicated that cell transplantation can be more successful when combined with gene therapy. 22, 23 The goal of this study was to increase the viability and potential therapeutic value of transplanted NSCs following SCI. We observed that GM-CSF overexpression in NSCs, carried out by a hypoxia-inducible vector, enhanced NSC survival both in vitro and in vivo. Furthermore, transplantation of these engineered NSCs into the hypoxic (ischemic) condition of the injured cord triggered the activation of the erythropoietin vector, leading to overexpression of GM-CSF by NSCs. This improved not only in vivo cell survival but also locomotor recovery by spinal injured adult rats. EpoSV-GM-CSF NSCs transplantation did not result in the formation of tumors during the 6 weeks of this study.
GM-CSF and its receptor are found on several types of nervous system cells, including microglia, astrocytes, oligodendrocytes, neurons and NSCs. Because GM-CSF is able to cross the blood-brain and blood-spinal cord barriers, 24 its role in the nervous system has been explored. As a pro-inflammatory hematopoietic cytokine, GM-CSF has diverse effects on cortical microglia, ranging from induction of proliferation to changes in morphology. GM-CSF can induce cell migration to areas of cell death. 25 Recently, GM-CSF has been suggested to promote survival of dopaminergic neurons in a murine model of Parkinson's disease, 13 and has even been thought to stimulate axonal outgrowth in paraplegic rats. 14 Although GM-CSF is commercially available and widely used for treating some types of cancer as a vaccine adjuvant, 26, 27 the therapeutic evaluation of GM-CSF within the hypoxic injured spinal cord has not been investigated. Here, we used GM-CSF overexpression in hypoxic conditions (Figure 2 ) to observe its possible neuroprotective effects in vitro (Figures 3 and 4) and in vivo ( Figure 5 ).
Gene expression systems that are more specific for injured tissue are desirable because it would not be reasonable to activate the gene within surrounding healthy tissue. The current findings suggest that the potentially detrimental hypoxic/ischemic stress that usually accompanies SCI could also be used as an injury-specific trigger for gene expression. This could then protect transplanted and possible host cells from the hypoxia. 7, 8, 28, 29 Several elements, such as the hypoxia-responsive untranslated region, [30] [31] [32] oxygen-dependant degradation domain sequence, 33, 34 RTP801 promoter 35 and Epo enhancer 31, 36 have been used to design hypoxia-inducible systems. We have previously confirmed that the Epo enhancer-based system increases gene expression specifically in hypoxic cells. In this study, we verified that Epo enhancer-based GM-CSF expression is tightly regulated in hypoxia, given that EpoSV-GM-CSF-transfected NSCs showed GM-CSF expression at basal levels in normoxia, but significantly increased the expression only in hypoxic environments (Figure 2) .
Using another hypoxic stimulus (CoCl 2 ), which is used as a hypoxia-mimicking reagent to target sterol synthesis, [37] [38] [39] we found GM-CSF overexpression by hypoxia to be a fundamental property of the engineered cells. Similar expression patterns of the secreted GM-CSF in hypoxia were observed by ELISA analysis in vitro. Therefore, this gene carrier system specific in hypoxia represents a safe gene therapy tool with a high potential for clinical application.
H 2 O 2 is a reactive oxidative species that participates in the development of ischemia, which includes SCI and neurodegenerative diseases like Parkinson's disease. 40, 41 When EpoSV-GM-CSF NSCs were treated with H 2 O 2 injury, we witnessed a protective effect on both un-differentiated and differentiated NSCs in hypoxia in vitro. Also in SCI, EpoSV-GM-CSF NSCs protected tissues from apoptosis. GM-CSF was previously reported as having a neuroprotective effect after staurosporin-induced apoptosis in retinal ganglion cells and in the vitreous bodies of Sprague-Dawley rats. 42 It has also been described to control glial scar composition and influence the survival and function of neighboring neurons. 43 Thus, it is possible that hypoxia-induced GM-CSF in EpoSV-GM-CSF NSCs protects the host organs by means of autocrine and paracrine effects. However, it is not presently known whether the proteins secreted by the EpoSV-GM-CSF NSCs themselves directly promote enhanced survival of neighboring host tissue cells. This requires further investigation. The present study also showed that the number of surviving NSCs in the control SV-GM-CSF NSCs and control NSCs groups at 2 weeks post-transplantation was much lower than in the EpoSV-GM-CSF NSCs group, suggesting that the death of transplanted NSCs continued after acute transplantation, whereas GM-CSF overexpression in SCI increased transplanted NSC survival. The pattern of antiapoptotic gene expression illustrated in Figure 5c illustrates the fact that GM-CSF overexpression in EpoSV-GM-CSF NSCs may contribute to NSC survival within the injured spinal cord through Bcl-2 and Bcl-xL induction. Previous studies have shown that GM-CSF decreased apoptotic activity by induction of Bcl-xL through the PI3K-Akt pathway in primary cortical neurons and human neuroblastoma cells in vitro. 44 Immunohistochemical analyses identified that MAP-2 was expressed in EpoSV-GM-CSF-transfected NSCs after transplantation ( Figure 6 ). We also observed significant locomotor recovery in the EpoSV-GM-CSF-transfected NSC-transplanted group, a new development in preceding reports that have stated that only GM-CSF could enhance locomoter function in the spinal cord contusion injury. 45 Because of the low survival rate of NSC in the SCI, 20, 21 in this study, we attempted to demonstrate NSC survivalenhancement by hypoxia-induced GM-CSF as a result of locomoter function improvement. We concluded that the enhanced in vivo recovery effect had been caused by two indistinguishable factors: hypoxia-induced GM-CSF, and GM-CSF-induced transplanted cell survival and differentiation in the SCI. This survival consequently contributed to the repair of the spinal cord.
Hence, our study demonstrates improvement in the survival of transplanted NSCs that overexpress GM-CSF. This suggests that NSCs overexpressing GM-CSF, tightly regulated by a hypoxia-inducible gene expression system, may point toward a clinically effective treatment of spinal cord injuries.
MATERIALS AND METHODS
Plasmid construction
Two plasmids, pBudSV-luciferase and pBudEpoSV-luciferase, were used as mother vectors 16 for SV-GM-CSF and EpoSV-GM-CSF constructs, respectively. The luciferase sequences from pBudSV-luc and pBudEpoSV-luc were each digested by Hind3 and Hpa1. Human GM-CSF CDS from pcDNA3-GM-CSF was obtained by Hind3 and EcoRV. The pcDNA3-GM-CSF plasmid was a generous gift from Prof Choi in the Department of Biomedical and Bioengineering Sciences, Inha University, Inchon, Korea. Each plasmid was ligated to GM-CSF (Figure 1a ) for 1 h at room temperature. The E. coli DH5a strain was used for competent cell transformations.
Cell culture and transfection
Mouse NSCs established from a 9-day-old mouse embryo (ATCC CRL-2925) were cultured in Dulbecco's modified Eagle's medium/F12 with 10% fetal bovine serum. Transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as previously described. 16 Briefly, in a 6-well plate, 1 day after seeding (300 000 cells per well), the transfection mixture of plasmid/ Lipofectamine 2000 (1:2.5, 4 mg DNA per well) was dropped into culture media. Media was changed after 4 h of incubation in normoxia (pO 2 , 21%) and subsequent experiments were performed. For differentiation, mNSCs was maintained in Dulbecco's modified Eagle's medium/F12 with 5% fetal bovine serum and 1 mM retinoic acid for 7 days. Media was changed every 2 days.
Hypoxia
A hypoxic environment was created by flushing a hypoxic gas mixture using a Forma Series II Water-Jacketed CO 2 Incubator (Thermo Fisher Scientific Inc., Waltham, MA, USA). Hypoxic conditions (pO 2 , 1%) are achieved in gas within 30 min after opening and closing of the door. The medium was pre-equilibrated to hypoxia for the study of the kinetics of hypoxia-responsive GM-CSF expression. Furthermore, a comparative study of hypoxia-responsive GM-CSF expression was performed using the hypoxia-mimicking reagent CoCl 2 .
PCR
Total RNA was extracted using Trizol reagent (Invitrogen). RNA (1 mg) was used to synthesize cDNA using a SuperScriptIII First-Strand Synthesis kit (Invitrogen). Briefly, for quantitative PCR, cDNA levels were quantified with SYBR green (Applied Biosystems, Foster City, CA, USA) using an ABI7500 sequence detection system (Applied Biosystems). PCR products were detected by incorporation of SYBR green and authenticated by the melt curve. Threshold cycle (C T ) numbers during the log phase of amplification were normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The relative expression in each sample was calculated by the 2-DDC T method. 46 For traditional reverse transcription-PCR, samples were amplified using a PCR machine (Applied Biosystems) using Taq polymerase (TaKaRa Bio, Inc., Shiga, Japan). GAPDH was used as a reference gene. Independent experiments were done in triplicate. The sequences of primers were as follows: GM-CSF forward(F): 5¢-ATGTTTGACCTCCAGGAGCC-3¢, GM-CSF, reverse(R): 5¢-TT GTAGTGGCTGGCCATCAT-3¢; GM-CSF a receptor F: 5¢-GGCCAGT GCGGTTCCTGGAC-3¢, GM-CSF a receptor R: 5¢-TCGCGTGTCCTCAGCC TCGA-3¢; GM-CSF b receptor F: 5¢-ACTCACATGGGGGCTGTGCTACA-3¢, GM-CSF b receptor R: 5¢-GTGCGCACACGGGCAGCATA-3¢; b-III tubulin F: 5¢-GGGCCTTTGGACACCTATTCA-3¢, b-III tubulin R: 5¢-GCCCTCTGTATA GTGCCCTTTG-3¢; GFAP F: 5¢-ACAGACTTTCTCCAACCTCCAGAT-3¢, GFAP R: 5¢-TCTTTACCACGATGTTCCTCTTGA-3¢; Bcl-2 F: 5¢-CGCGTTG GCCCTTCGGAGTT-3¢, Bcl-2 R: 5¢-ACACTCCGGCTTCACTGAGA-3¢; Bcl-xL F: 5¢-TGAAGCAAGCGCTGAGAGAG-3¢, Bcl-xL R: 5¢-ACTGAAGAGTGAGCC CAGCA-3¢; GAPDH F: 5¢-AGACTGTGGATGGCCCCTCT-3¢, GAPDH R: 5¢-T CAGATCCACGACGGACACA-3¢.
ELISA
Using a kit for the ELISA for GM-CSF (R&D, Minneapolis, MN, USA), following the manufacturer's protocol, each designated plate was first rinsed with 100 ml of incubation buffer. The prepared standards or samples (100 ml per well) were added to the plate and incubated at room temperature for 2 h. Biotin-conjugated solution (biotinylated anti-GM-CSF, 200 ml per well) was added to each well and incubated for 1.5 h at room temperature. At 30 min after the addition of 200 ml of substrate solution, stop solution was added. Absorbance at 450 nm was measured using an ELISA reader. Secreted GM-CSF levels from transfected NSCs were calculated using a corresponding standard curve. Independent experiments were done in triplicate.
TUNEL assay
TUNEL staining protocol was based on the ApopTag Plus Fluorescenin In Situ Apoptosis Detection Kit (Chemicon, Temecula, CA, USA). Briefly, cultured NSCs were fixed in 4% paraformaldehyde for 10 min, followed by post-fixation with ethanol and acetic acid (2:1, v/v). Working strength enzyme was added for 1 h of incubation, after which stop/wash buffer was applied. Samples were then incubated with working strength anti-digoxigenin-conjugated mixture for 30 min in a dark room. After washing, slides were mounted with 4¢,6-diamidino-2-phenylindole. Fluorescence images were collected using an Olympus DP71 camera (ZX71, Olympus, Tokyo, Japan).
Fluorescent-activated cell sorting analysis
To confirm the progress of apoptosis, 2Â10 6 mNSCs were harvested and washed with PBS. After being centrifuged at 1000Âg for 5 min, mNSCs were incubated with annexin-V fluorescein isothiocyanate in binding buffer (Biobud, Seoul, Republic of Korea). After 15 min, NSCs were centrifuged at 1000Âg for 5 min and washed in cold binding buffer. Analysis was performed using a FACSCalibur (Becton Dickinson, San Jose, CA, USA) and Cell Quest software (Becton Dickinson).
Immunocytochemistry
NSCs were washed three times for 3 min each with PBS, fixed in 4% paraformaldehyde for 15 min and treated with 0.3% Triton X-100 with 0.1% bovine serum albumin for 15 min. Subsequently, NSCs were blocked with 10% normal donkey serum for 30 min and incubated with mouse anti-MAP2 (1:500, Chemicon). After cells were washed completely, NSCs were incubated with an anti-mouse secondary antibody conjugated with fluorescein isothiocyanate for 1 h. Cells were washed again . Fluorescence images were collected using an Olympus DP71 camera (ZX71, Olympus) or a laser scanning confocal microscope (LSM700, Carl Zeiss, Jena, Germany).
SCI
All procedures were approved by the Animal Care and Use Committee of the Yonsei University College of Medicine. Adult male Sprague-Dawley rats (250 g, OrientBio, Kyung ki do, Korea) were anesthetized using Zoletil 50 (10 mg per rat, Virbac, France). Laminectomies were performed at the T9 level. The intact, exposed spinal cord was compressed with a vascular clip (width, 2 mm; occlusion pressure, 30 g) for 10 min, as previously described. 7 After removing the clip, transfected NSCs (300 000 cells per 5 ml) were transplanted into the injured or non-injured epicenter of the spinal cord (left of the posterior median sulcus on the T9 level) using a 5-ml Hamilton syringe. All animals received cyclosporine (10 mg kg À1 , Chong Kun Dang Pharm, Seoul, Korea) every day after transplantation. At weeks 2 and 6 after SCI, animals were anesthetized using Zoletil 50, transcardially perfused with saline, and fixed with 4% paraformaldehyde. Spinal cord tissue, including the injury epicenter and transplanted sites, was removed and stored in 4% paraformaldehyde for further processing.
Cryostat sections and in vivo image acquisition
During cryoprotection, tissues were placed in a 30% sucrose solution for 1 day, and rapidly frozen in embedding medium (Optimal Cutting Temperature compound, Sakura Finetek, Torrance, CA, USA). Then 100 serial sagittal sections of each spinal cord were cut on a cryostat at 14 mm increments from left to right, and collected on microscope slides in order. Fluorescence images of transplanted NSCs were acquired using an Olympus ZX71 microscope equipped with a DP71 camera. After 20 sections from each group (DsRed-NSC, SV-GM-CSF NSC, EpoSV-GM-CSF NSC) were selected from the area of transplantation (35-54th), the images were used to evaluate fluorescence intensity using MetaMorph software (Universal Imaging, West Chester, PA, USA). To summarize, the intensity (of fluorescence) had been used to establish a threshold, and the areas of the images that were highlighted represented cells that met this threshold of intensity. Subsequently, these areas of DsRed-labeled cells were examined by means of pixcels (which yielded the optical densities).
Functional testing
A subset of animals underwent behavioral analysis to assess the extent of locomotor recovery. The Basso, Beattie and Bresnahan locomotor rating scale was used to evaluate the quality of hindlimb movement during open field locomotion. Basso, Beattie and Bresnahan scores were assigned from 1 to 6 weeks after SCI. A total of 48 rats completed all rounds of Basso, Beattie and Bresnahan tests (PBS group, n¼12; NSC group, n¼12; SV-GM-CSF group, n¼12; EpoSV-GM-CSF, n¼12).
Statistical analysis
One-way analysis of variance tests were used to compare experimental groups. Post-hoc comparisons of subgroups were done with the Student-NewmanKeuls test. The data are expressed as mean ± s.d. All data were analyzed using the MedCalc Program (Medcalc Software, Mariakerke, Belguim). A P-value o0.05 was considered statistically significant.
